Vaccine News and Research

Latest Vaccine News and Research

mRNA vaccines offer protection against influenza A virus infections in various animal models

CureVac GmbH, a clinical stage biopharmaceutical company developing a new class of therapies and vaccines based on mRNA, and the German Federal Research Institute for Animal Health, Friedrich-Loeffler-Institute (FLI), Germany, today announced that mRNA vaccines (RNActive) based on the company's RNA technology platform have the potential to provide effective protection against infectious diseases.

26 Nov 2012

Online flu survey launched in the UK

Does “man flu” exist? How effective is the flu vaccine? And do pets keep you healthy? These are just some of the questions scientists from the London School of Hygiene & Tropical Medicine want to explore as they launch a nationwide flu survey.

22 Nov 2012

Single dose of Medicago's vaccine could offer cross-protection against flu

Researchers recently found that a single dose of a vaccine being developed by Medicago, Inc., a publicly traded biopharmaceutical company, could protect against not only the avian influenza (H5N1) strain it was designed for, but also another H5N1 strain and a strain of a different flu subtype, called H2N2.

22 Nov 2012

Dropping of cold chain requirement for meningitis vaccine will improve access, IRIN reports

IRIN examines how the WHO's recent declaration that the MenAfriVac meningitis A vaccine can be transported or stored for up to four days without refrigeration will affect immunization campaigns in Africa's meningitis belt, which runs from Senegal to Ethiopia.

22 Nov 2012

Genetic study: Novel coronavirus most closely related to viruses in bats

The virus that is causing alarm among global public health authorities after it killed a man in Jeddah, Saudi Arabia earlier this year and is now linked to two other cases of disease is a novel type of coronavirus most closely related to viruses found in bats, according to a genetic analysis to be published in mBio-, the online open-access journal of the American Society for Microbiology, on November 20.

22 Nov 2012

Promising results for pneumococcal vaccine

Research published in The Lancet shows that the PHiD-CV10 vaccine is highly effective at protecting children against invasive pneumococcal disease.

21 Nov 2012

French oil company funding rotavirus research in Congo

"Medical researchers in the Republic of the Congo (Congo-Brazzaville) have been empowered to set their own research priorities through a funding mechanism backed by a French oil company, according to scientists speaking at the second European and Developing Countries Clinical Trials Partnership (EDCTP), in South Africa this month," SciDev.Net reports.

21 Nov 2012

Sudan launches yellow fever vaccination campaign to immunize 2.4M

"Sudan has launched a massive vaccination campaign to immunize 2.4 million people against an outbreak of yellow fever in the restive region of Darfur, the U.N. said Monday," according to the Associated Press.

21 Nov 2012

Novartis receives FDA approval for Flucelvax to prevent seasonal influenza

The U.S. Food and Drug Administration announced today the approval of Flucelvax, the first seasonal influenza vaccine licensed in the United States produced using cultured animal cells, instead of fertilized chicken eggs. Flucelvax is approved to prevent seasonal influenza in people ages 18 years and older.

21 Nov 2012

Emory University, Georgia Tech to establish Malaria Host-Pathogen Interaction Center

The National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, has awarded a five-year contract of up to $19.4 million, depending on contract options exercised, to establish the Malaria Host-Pathogen Interaction Center (MaHPIC).

20 Nov 2012

Texas Biomed applies patent for new genetically-engineered vaccine strategy to prevent HIV

The Texas Biomedical Research Institute in San Antonio has applied for a patent for a genetically-engineered vaccine strategy to prevent HIV infection that targets the outer layers of body structures that are the first sites of contact with the virus.

20 Nov 2012

Aradigm’s Lipoquin provides full protection in murine models of pneumonic plague

Scientists from the UK Defence Science and Technology Laboratory (Dstl) report, in a preliminary study, that they have demonstrated that a single dose of Aradigm Corporation's liposomal ciprofloxacin formulation Lipoquin administered 24 hours after exposure to a lethal dose of the bacterium Yersinia pestis provided full protection in a murine model of pneumonic plague.

20 Nov 2012

Interim results from RTS,S vaccine on-going phase III trial on malaria

According to the World Health Organization (WHO), more than 250 million clinical malaria cases are attributed to Plasmodium falciparum (Pf) annually, with over 1.1 million deaths in sub-Saharan Africa alone.

17 Nov 2012

New pneumococcal vaccine highly effective in infants

A new conjugate vaccine is highly effective (93–100%) at preventing invasive pneumococcal disease (IPD; meningitis, sepsis, bacteremic pneumonia, and other blood-borne infections) in infants younger than 2 years who are the most vulnerable to infection, according to new research published Online First in The Lancet.

16 Nov 2012

Vaccinating families could protect young babies against RSV infection

Research by the University of Warwick indicates that vaccinating families could protect young babies against a common winter virus which can be fatal for infants under six months.

16 Nov 2012

Meningitis vaccine declared usable without refrigeration for up to four days

"In a breakthrough for the fight against meningitis in poor countries, researchers say the WHO has ruled that a key vaccine can be transported or stored for up to four days without refrigeration," Agence France-Presse reports.

16 Nov 2012

Study finds specific way in which Salmonella counteract defense mechanisms of human cells

A new study by researchers at Imperial College London has identified a way in which Salmonella bacteria, which cause gastroenteritis and typhoid fever, counteract the defence mechanisms of human cells.

16 Nov 2012

Number of polio cases worldwide reaches record low, but experts say challenges remain

"The number of polio cases worldwide reached a record low in 2012, giving experts confidence that the disease can finally be eradicated, according to presentations made at" the annual meeting of the American Society of Tropical Medicine and Hygiene (ASTMH) in Atlanta on Tuesday, Agence France-Presse reports (11/13).

15 Nov 2012

Money spent on presidential campaigns could go far in fighting NTDs

Noting that an estimated $2 billion was spent on the U.S. presidential campaigns, Peter Hotez, president of the Sabin Vaccine Institute and founding dean of the National School of Tropical Medicine at the Baylor College of Medicine, writes in the Huffington Post "Healthy Living" blog, "Many of us in the global health community can only look upon that $2 billion figure in awe because of the potential for those dollars to be repurposed to immediately and dramatically improve the lives of the poorest people who suffer from disease."

15 Nov 2012

Yellow fever kills more than 100 people in Darfur; WHO, health ministry to provide immunizations

"More than two million people in Sudan's Darfur region will be vaccinated against a rare yellow fever outbreak suspected of killing 107 people since late September, health officials said on Tuesday," Agence France-Presse/France 24 reports (11/13). In a joint statement, the WHO and the Sudanese Ministry of Health said the mosquito-borne disease has spread throughout the western territory, which "has been plagued by conflict since rebels took up arms in 2003," Reuters notes.

15 Nov 2012